For independent traders and private investors operating in the micro-cap and swing trading space, tracking intraday catalysts is essential for managing risk and capturing momentum. Today’s scan focuses on a specific basket of equities—primarily trading near or below the $5 threshold—that are currently experiencing elevated volume due to clinical updates, earnings reports, or recent capital restructuring.
Here is the factual breakdown of today’s market movers based on the latest available news.
1. Cardiol Therapeutics Inc. ($CRDL)
$CRDL FEATURED IN THE WALLSTVAULT.COM
Current Price Target Range: ~$1.38 Sector: Biotechnology
Today’s Catalyst & Background: Cardiol Therapeutics remains a primary watch for biotech momentum traders. The company is actively expanding its U.S. clinical network for the Phase III MAVERIC trial. Cardiol currently holds an Investigational New Drug (IND) authorization from the US FDA to evaluate its lead small-molecule drug candidate, CardiolRx (an oral solution), for two heart conditions: recurrent pericarditis and acute myocarditis. Institutional coverage remains largely bullish on the technical and fundamental setups as the clinical pipeline advances.
Get updates on $CRDL from our trading desk by singing up below for free…
2. 3 E Network Technology Group Limited ($MASK)
Current Price Target Range: ~$1.45 Sector: Technology / AI Infrastructure Today’s Catalyst & Background:$MASK is seeing renewed retail and institutional interest following significant corporate developments this week. Yesterday, the company announced the initial closing of $920,000 from a newly signed $1.3 million convertible note agreement with an institutional investor (notes carrying an 8% original-issue-discount). Furthermore, the company recently announced that earthworks and site clearance have officially commenced on their new 6MW AI data center project in Finland. Crucially for traders monitoring listing requirements, $MASK has successfully regained compliance with Nasdaq’s minimum bid price rule as of last month.
3. ARC Group Acquisition I Corp. ($ARCL)
Current Price Target Range: Newly Listed Sector: Special Purpose Acquisition Company (SPAC) Today’s Catalyst & Background: While traditional SPAC units list at $10, $ARCL is triggering heavy radar pings across catalyst scans today following its market debut. The blank-check company officially closed its initial public offering on the Nasdaq this week, successfully selling 12,075,000 units to raise $120.8 million. It is a key ticker to watch for future merger targets or definitive agreement announcements in the coming quarters.+1
4. Backblaze, Inc. ($BLZE)
Current Price Target Range: ~$4.64 Sector: Cloud Storage & Data Today’s Catalyst & Background: Backblaze is experiencing heavy volume today following the release of its Q1 2026 earnings late yesterday, May 4. The company reported a revenue beat of $38.67 million for the quarter (compared to consensus estimates of $37.78 million) and an EPS of $0.04. Operationally, Backblaze is actively scaling its infrastructure to handle demanding AI workloads, upgrading its network port capacities significantly to match rising compute demand across its 500,000+ customer base.+1
5. Grab Holdings Limited ($GRAB)
Current Price Target Range: ~$3.67 Sector: Mobility & Delivery Services Today’s Catalyst & Background: Grab Holdings is in the spotlight today following a strong Q1 2026 earnings release this morning, May 5. The Southeast Asian superapp beat revenue estimates, posting $955 million for the quarter (a 24% year-over-year increase) and recording a net profit of $120 million. The positive performance was driven by robust metrics in both ride-hailing and food delivery, augmented by new promotional bundles and AI features. Management has reaffirmed its full-year 2026 guidance, projecting total revenue between $4.04 billion and $4.10 billion.
Disclaimer: This research memo is strictly for investor awareness and private retail trading discussion. The information provided is based on factual market scans and publicly available data as of May 5, 2026. It is not produced by a licensed institutional analyst or broker-dealer and should not be construed as registered financial advice.
LEGAL COMPLIANCE & DISCLOSURES
NOT FINANCIAL ADVICE – EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY All information provided by News On Wall Street (the “Publisher”) is strictly for educational and informational purposes only. Nothing contained herein constitutes, or is intended to constitute, investment advice, a recommendation to buy, sell, or hold any security, or a solicitation of any kind. The Publisher is not a registered investment adviser, broker-dealer, or financial planner with any regulatory agency. We do not provide personalized investment recommendations and have no fiduciary duty to any reader or subscriber.
You should consult with a qualified, licensed financial professional (such as a registered investment adviser or broker-dealer) who can assess your individual financial situation, risk tolerance, investment objectives, and tax consequences before making any investment decision. Investing in micro-cap biotechnology stocks like Cardiol Therapeutics ($CRDL) carries extreme risk, including the potential for total loss of principal. Biotech companies frequently experience total failure of clinical programs, regulatory rejection, massive dilution, delisting, or bankruptcy. Volatility can be extreme, with shares sometimes moving 50% or more in a single day on news events.
HIGH-RISK WARNING SPECIFIC TO BIOTECHNOLOGY INVESTING Biotechnology investing is inherently binary and speculative. Most clinical-stage companies never generate profits, never receive regulatory approval, and ultimately result in significant or total investor losses. Factors that could cause actual results to differ materially from any expectations expressed here include (but are not limited to): failure of Phase II or Phase III clinical trials (such as the ARCHER or MAVERIC trials referenced), delays or denial of FDA or other regulatory approvals, manufacturing issues, competition from larger pharmaceutical companies, intellectual property challenges, dilution from future financings, changes in healthcare policy, clinical safety concerns, adverse events, inability to secure additional funding, loss of key personnel, and general market or economic conditions. Past clinical data is not a guarantee of future success in larger trials or commercialization.
FORWARD-LOOKING STATEMENTS SAFE HARBOR This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “project,” “may,” “will,” “could,” “should,” “potential,” “intend,” “forecast,” “target,” or similar expressions.
All forward-looking statements are based on current expectations, estimates, projections, and assumptions that involve risks and uncertainties. These statements speak only as of the date they are made, and the Publisher undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those expressed or implied due to the numerous risks outlined above and in Cardiol’s SEC filings (10-K, 10-Q, 8-K, etc.). Nothing in this report is a guarantee of future performance, clinical success, regulatory approval, commercialization, or stock price appreciation.
SEC RULE 17(b) DISCLOSURE (PAID PROMOTION / AWARENESS CAMPAIGN) News On Wall Street (the “Publisher”) has been compensated $100,000 in cash by Cardiol Therapeutics Inc. (“Cardiol” or the “Company”) for the creation, distribution, and ongoing awareness efforts related to this report and associated content. This compensation covers the period from April 7, 2026, through May 27, 2026. The payment was made directly by the Company (or its agents) to the Publisher and constitutes a material conflict of interest.
This entire communication is a paid advertisement / sponsored awareness campaign. The Publisher was compensated specifically to publish, publicize, and circulate information regarding Cardiol’s securities. Under Section 17(b) of the Securities Act of 1933, this disclosure is required. Investors must assume that the Publisher’s objectivity is influenced by this relationship. THIS IS NOT INDEPENDENT RESEARCH. It is commissioned, paid-for promotional material. The Publisher is not acting as an independent analyst and does not claim to provide unbiased or impartial analysis.
CONFLICT OF INTEREST DISCLOSURE The Publisher and/or its principals, affiliates, officers, directors, employees, family members, or other associated parties may currently hold, or may in the future purchase or sell, positions in Cardiol Therapeutics ($CRDL) or any other securities mentioned without prior or subsequent notice to readers. The Publisher may buy or sell shares at any time, including before, during, or after the distribution of this report. This creates an inherent conflict of interest.
INFORMATION SOURCES, ACCURACY, AND LIABILITY Information in this report is derived from public sources believed to be reliable (Company press releases, SEC filings, etc.). However, the Publisher makes no representation or warranty as to the accuracy, completeness, or timeliness of any information provided. To the fullest extent permitted by law, News On Wall Street, its officers, directors, and affiliates shall not be liable for any direct, indirect, or consequential damages arising out of the use of this report, including trading losses or loss of profits.
PERFORM YOUR OWN DUE DILIGENCE (DYOR) Always conduct your own thorough independent research. Review Cardiol’s latest SEC filings at www.sec.gov, consult multiple independent sources, and speak with your own financial and legal advisors before investing. Do not rely solely on any paid promotional material.
By continuing to read or act upon any information provided by News On Wall Street, you acknowledge that you have read, understood, and agreed to this full Legal Compliance & Disclosures section in its entirety.
